Agile Therapeutics, Inc.
101 Poor Farm Road
Princeton
New Jersey
08540
United States
Tel: 609-683-1880
Fax: 609-683-1855
Website: http://www.agiletherapeutics.com/
Email: info@agiletherapeutics.com
248 articles about Agile Therapeutics, Inc.
-
Agile Therapeutics Announces the Availability of Twirla® through FPA Women’s Health
6/15/2023
Agile Therapeutics, Inc., a women's healthcare company, announced that Twirla will become available through FPA Women’s Health.
-
Agile Therapeutics Announces New Agreement with vitaCare® Prescription Services to Improve Access to Twirla®
6/13/2023
Agile Therapeutics, Inc., a women's healthcare company, announced an agreement with vitaCare Prescription Services, a wholly owned subsidiary of GoodRx, to expand patient access and streamline fulfillment for Twirla transdermal system.
-
Agile Therapeutics Announces Closing of $7.5 Million Public Offering
5/25/2023
Agile Therapeutics, Inc., a women's healthcare company, announced the closing of its previously announced public offering of an aggregate of 1,896,286 shares of its common stock, together with accompanying common stock warrants, at a public offering price of $3.9551 per share and accompanying warrants.
-
Agile Therapeutics Announces Pricing of $7.5 Million Public Offering
5/23/2023
Agile Therapeutics, Inc., a women's healthcare company, announced the pricing of its public offering of an aggregate of 1,896,286 shares of its common stock, together with accompanying common stock warrants, at a public offering price of $3.9551 per share and accompanying warrants.
-
Agile Therapeutics Reports First Quarter 2023 Financial Results And Provides Corporate Update
5/11/2023
Agile Therapeutics, Inc., a women's healthcare company, reported financial results for the three months ended March 31, 2023 and provided a corporate update.
-
Agile Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on Thursday, May 11, 2023
5/8/2023
Agile Therapeutics, Inc., a women's healthcare company, announced it will report first quarter 2023 financial results after the market close on Thursday, May 11, 2023.
-
Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023
4/28/2023
Agile Therapeutics, Inc., a women's healthcare company, announced preliminary expectations for first quarter 2023 Twirla® demand, net revenue and operating expenses.
-
Agile Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
4/26/2023
Agile Therapeutics, Inc. announced that it has received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market, informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550.
-
Agile Therapeutics Announces 1-For-50 Reverse Stock Split
4/10/2023
Agile Therapeutics, Inc., a women's healthcare company, announced that its board of directors approved a 1-for-50 reverse stock split, to be effective 4:00 p.m. on Monday, April 10, 2023.
-
Agile Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Corporate Update
3/22/2023
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three and twelve months ended December 31, 2022 and provided a corporate update.
-
Agile Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on Wednesday, March 22, 2023Live Conference Call and Webcast at 4:30 p.m. ET
3/21/2023
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2022 financial results after the market close on Wednesday, March 22, 2023.
-
Agile Therapeutics Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement
2/27/2023
Agile Therapeutics, Inc. announced that it has received written notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC granting the Company’s request for a 180-day extension to regain compliance under Nasdaq Listing Rule 5550.
-
Agile Therapeutics Provides Clinical Update on Twirla and Status of Pipeline Evaluation
2/1/2023
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today provided an update on the Twirla® post-marketing studies and status of its ongoing evaluation of the Company’s pipeline.
-
Agile Therapeutics Announces Distribution of Series C Preferred Stock to its Holders of Common Stock
1/26/2023
Agile Therapeutics, Inc. announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 p.m.
-
Agile Therapeutics Provides Updates on 2022 Twirla Performance and 2023 Commercial Plan
1/9/2023
Agile Therapeutics, Inc., a women's healthcare company, provided an update on Twirla for 2022 and its commercial plan for 2023.
-
Agile Therapeutics To Present At The Upcoming RHK Capital Disruptive Growth Conference
12/1/2022
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that it will participate in the RHK Capital Disruptive Growth Conference being held in the offices of Reed Smith in New York, NY on December 5-6, 2022.
-
Agile Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
11/7/2022
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three months ended September 30, 2022 and provided a corporate update.
-
Agile Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on Monday, November 7, 2022
10/26/2022
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report third quarter 2022 financial results after the market close on Monday, November 7, 2022.
-
Agile Therapeutics Announces Reorganization of Leadership Team
10/7/2022
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that it has reorganized and streamlined its executive leadership team to align with its business plan to promote Twirla® (levonorgestrel and ethinyl estradiol) transdermal system growth.
-
Agile Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
9/6/2022
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced that Chairman and Chief Executive Officer Al Altomari and Vice President of Marketing Amy Welsh will present at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022 in New York, NY.